The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents

Psychoneuroendocrinology

Volumn 38, Issue 8, 2013, Pages 1259-1270

  Egecioglu, Emil ^a   Steensland, Pia ^b   Fredriksson, Ida ^b   Feltmann, Kristin ^b   Engel, Jörgen A ^a   Jerlhag, Elisabet ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alcoholism. Alcohol; Dopamine; Exenatide; Exendin 4; Liraglutide; Reward

Indexed keywords

ALCOHOL; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1;

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; IN VIVO STUDY; LOCOMOTION; LOW DRUG DOSE; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD;

ANIMALS; CHOICE BEHAVIOR; CONDITIONING (PSYCHOLOGY); CONDITIONING, OPERANT; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; ETHANOL; GLUCAGON-LIKE PEPTIDE 1; MALE; MICE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PEPTIDES; RATS; REWARD; SELF ADMINISTRATION; VENOMS;

EID: 84878632805     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.11.009     Document Type: Article

References (64)

1. Alhadeff A.L., Rupprecht L.E., Hayes M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153(2):647-658.
2. Alvarez E., Roncero I., Chowen J.A., Thorens B., Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J. Neurochem. 1996, 66(3):920-927.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
4. Barrera J.G., D'Alessio D.A., Drucker D.J., Woods S.C., Seeley R.J. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 2009, 58(12):2820-2827.
5. Blednov Y.A., Walker D., Harris R.A. Blockade of the leptin-sensitive pathway markedly reduces alcohol consumption in mice. Alcohol. Clin. Exp. Res. 2004, 28(11):1683-1692.
6. Bowers M.S., Hopf F.W., Chou J.K., Guillory A.M., Chang S.J., Janak P.H., Bonci A., Diamond I. Nucleus accumbens AGS3 expression drives ethanol seeking through G betagamma. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(34):12533-12538.
7. Brubaker P.L., Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 2003, 81(11):1005-1012.
8. Cagniard B., Murphy N.P. Affective taste responses in the presence of reward- and aversion-conditioned stimuli and their relationship to psychomotor sensitization and place conditioning. Behav. Brain Res. 2012, 236(1):289-294.
9. Carnicella S., Amamoto R., Ron D. Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 2009, 43(1):35-43.
10. Davis J.F., Schurdak J.D., Magrisso I.J., Mul J.D., Grayson B.E., Pfluger P.T., Tschoep M.H., Seeley R.J., Benoit S.C. Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats. Biol. Psychiatry 2012, 72(5):354-360.
11. Daws L.C., Avison M.J., Robertson S.D., Niswender K.D., Galli A., Saunders C. Insulin signaling and addiction. Neuropharmacology 2011, 61(7):1123-1128.
12. Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 2012, 32(14):4812-4820.
13. Dossat A.M., Lilly N., Kay K., Williams D.L. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J. Neurosci. 2011, 31(41):14453-14457.
14. Engel J.A., Fahlke C., Hulthe P., Hard E., Johannessen K., Snape B., Svensson L. Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonists. J. Neural Transm. 1988, 74(3):181-193.
15. Erreger K., Davis A.R., Poe A.M., Greig N.H., Stanwood G.D., Galli A. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol. Behav. 2012, 106(4):574-578.
16. Ertelt T.W., Mitchell J.E., Lancaster K., Crosby R.D., Steffen K.J., Marino J.M. Alcohol abuse and dependence before and after bariatric surgery: a review of the literature and report of a new data set. Surg. Obes. Relat. Dis. 2008, 4(5):647-650.
17. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1996, Academic Press, New York.
18. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281(14):1318-1325.
19. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7(11):2294-2300.
20. Graham D.L., Erreger K., Galli A., Stanwood G.D. GLP-1 analog attenuates cocaine reward. Mol. Psychiatry 2012, http://dx.doi.org/10.1038/mp.2012.141 [Epub ahead of print].
21. Gutniak M., Orskov C., Holst J.J., Ahren B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992, 326(20):1316-1322.
22. Hayes M.R., Bradley L., Grill H.J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009, 150(6):2654-2659.
23. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149(8):4059-4068.
24. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87(4):1409-1439.
25. Holst J.J., Vilsboll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell Endocrinol. 2009, 297(1-2):127-136.
26. Jerlhag E., Egecioglu E., Dickson S.L., Andersson M., Svensson L., Engel J.A. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward. Addict. Biol. 2006, 11(1):45-54.
27. Jerlhag E., Egecioglu E., Landgren S., Salome N., Heilig M., Moechars D., Datta R., Perrissoud D., Dickson S.L., Engel J.A. Requirement of central ghrelin signaling for alcohol reward. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(27):11318-11323.
28. Kanoski S.E., Fortin S.M., Arnold M., Grill H.J., Hayes M.R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152(8):3103-3112.
29. Kanoski S.E., Rupprecht L.E., Fortin S.M., De Jonghe B.C., Hayes M.R. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012, 62(5-6):1916-1927.
30. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27(3):313-318.
31. Kaur S., Ryabinin A.E. Ghrelin receptor antagonism decreases alcohol consumption and activation of perioculomotor urocortin-containing neurons. Alcohol. Clin. Exp. Res. 2010, 34(9):1525-1534.
32. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2(8571):1300-1304.
33. Kulkosky P.J. Effect of cholecystokinin octapeptide on ethanol intake in the rat. Alcohol 1984, 1(2):125-128.
34. Landgren S., Simms J.A., Hyytia P., Engel J.A., Bartlett S.E., Jerlhag E. Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. Addict. Biol. 2012, 17(1):86-94.
35. Lewis M.J., Johnson D.F., Waldman D., Leibowitz S.F., Hoebel B.G. Galanin microinjection in the third ventricle increases voluntary ethanol intake. Alcohol. Clin. Exp. Res. 2004, 28(12):1822-1828.
36. Malendowicz L.K., Nussdorfer G.G., Nowak K.W., Ziolkowska A., Tortorella C., Trejter M. Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int. J. Mol. Med. 2003, 12(2):237-241.
37. Matsuyama T., Komatsu R., Namba M., Watanabe N., Itoh H., Tarui S. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res. Clin. Pract. 1988, 5(4):281-284.
38. McKee S.A., Harrison E.L., O'Malley S.S., Krishnan-Sarin S., Shi J., Tetrault J.M., Picciotto M.R., Petrakis I.L., Estevez N., Balchunas E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry 2009, 66(2):185-190.
39. McMahon L.R., Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 1998, 274(1 Pt 2):R23-R29.
40. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403(2):261-280.
41. Mitchell J.M., Teague C.H., Kayser A.S., Bartlett S.E., Fields H.L. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012, 223(3):299-306.
42. Novak U., Wilks A., Buell G., McEwen S. Identical mRNA for preproglucagon in pancreas and gut. Eur. J. Biochem. 1987, 164(3):553-558.
43. Perez-Tilve D., Gonzalez-Matias L., Alvarez-Crespo M., Leiras R., Tovar S., Dieguez C., Mallo F. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56(1):143-151.
44. Rada P., Avena N.M., Leibowitz S.F., Hoebel B.G. Ethanol intake is increased by injection of galanin in the paraventricular nucleus and reduced by a galanin antagonist. Alcohol 2004, 33(2):91-97.
45. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56(1):8-15.
46. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res. 2010, 1350:18-34.
47. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 1993, 18(3):247-291.
48. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150(3):1174-1181.
49. Sanchis-Segura C., Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict. Biol. 2006, 11(1):2-38.
50. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008, 57(8):2046-2054.
51. Schirra J., Kuwert P., Wank U., Leicht P., Arnold R., Goke B., Katschinski M. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc. Assoc. Am. Physicians 1997, 109(1):84-97.
52. Simms J.A., Steensland P., Medina B., Abernathy K.E., Chandler L.J., Wise R., Bartlett S.E. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol. Clin. Exp. Res. 2008, 32(10):1816-1823.
53. Soderpalm B., Lof E., Ericson M. Mechanistic studies of ethanol's interaction with the mesolimbic dopamine reward system. Pharmacopsychiatry 2009, 42(Suppl. 1):S87-S94.
54. Sonne D.P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 2008, 146(1-3):243-249.
55. Steensland P., Fredriksson I., Holst S., Feltmann K., Franck J., Schilstrom B., Carlsson A. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol. Psychiatry 2012, 72(10):823-831.
56. Steensland P., Simms J.A., Holgate J., Richards J.K., Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(30):12518-12523.
57. Steensland P., Simms J.A., Nielsen C.K., Holgate J., Bito-Onon J.J., Bartlett S.E. The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS ONE 2010, 5(9).
58. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., Moller M., Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 1996, 271(4 Pt 2):R848-R856.
59. Thiele T.E., Stewart R.B., Badia-Elder N.E., Geary N., Massi M., Leibowitz S.F., Hoebel B.G., Egli M. Overlapping peptide control of alcohol self-administration and feeding. Alcohol. Clin. Exp. Res. 2004, 28(2):288-294.
60. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42(11):1678-1682.
61. Tupala E., Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(8):1221-1247.
62. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379(6560):69-72.
63. Volkow N.D., Li T.K. Drug addiction: the neurobiology of behaviour gone awry. Nat. Rev. Neurosci. 2004, 5(12):963-970.
64. Wise R.A. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia 1973, 29(3):203-210.